p53 Status Predicts the Efficacy of Postoperative Oral Administration of Tegafur for Completely Resected Non-small Cell Lung Cancer†
- 1 April 1999
- journal article
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 90 (4) , 432-438
- https://doi.org/10.1111/j.1349-7006.1999.tb00766.x
Abstract
Although postoperative adjuvant therapy for non‐small cell lung cancer (NSCLC) had not been reported to be effective, it has been reported recently that oral administration of tegafur (1‐[2‐tetrahydrofuryl]‐5‐fluorouracil, FT) may improve the postoperative prognosis. In the present paper, to examine whether p53 status affects the efficacy of FT as postoperative adjuvant chemotherapy for NSCLC, a total of 236 consecutive patients with completely resected pathologic stage I–IIIa NSCLC were retrospectively reviewed. p53 status was determined by immunohistochemical staining. For all patients, the 5‐year survival rate of patients with FT administration (FT group) was 78.1%, being significantly higher than that (69.1%) of patients without FT administration (control group) (P=0.046). For patients without immunohistochemical evidence of p53 overexpression, the 5‐year survival rate in the FT group was 87.1%, being significantly higher than that (74.0%) in the control group (P=0.036). This demonstrates an improvement of postoperative prognosis by FT administration. On the other hand, for patients with p53 overexpression, there was no significant difference in the postoperative prognosis between the FT group and the control group (5‐year survival rate 63.2% and 60.1%, respectively; P=0.514), demonstrating that FT administration was not effective for these patients. In conclusion, p53 status may be useful for predicting the efficacy of postoperative adjuvant chemotherapy using FT. A prospective randomized study stratified by p53 status is needed to clarify the effect of postoperative FT administration.Keywords
This publication has 34 references indexed in Scilit:
- Lewis Y antigen expression and postoperative survival in non–small cell lung cancerThe Annals of Thoracic Surgery, 1998
- Time trends and survival after operations for primary lung cancer from 1976 through 1990The Journal of Thoracic and Cardiovascular Surgery, 1996
- Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1995
- A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study)European Journal of Surgical Oncology, 1995
- Postoperative adjuvant therapy for non-small cell lung cancer: a consensus reportLung Cancer, 1994
- p53 Status and the Efficacy of Cancer Therapy in VivoScience, 1994
- p53 in Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 1994
- Mutations of the p53 Gene as a Predictor of Poor Prognosis in Patients With Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 1993
- Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6Nature, 1991
- The p53 tumour suppressor geneNature, 1991